← All trials
NCT02399306
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2015
- Primary completion
- Jun 1, 2017
- Completion date
- Jun 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 210
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of Electronic Science and Technology of ChinaLead sponsor
- University of Electronic Science and Technology of ChinaReponsible party - principal investigator
- University of Electronic Science and Technology of ChinaStudy chair
- Wuhan UniversityCollaborator
- Henan Medical UniversityCollaborator
- Shandong Tumor HospitalCollaborator
- Central South UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Peking UniversityCollaborator
- Hebei UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.